Cannabis Stocks Forum & Discussion

Welcome to the Cannabis Investing Newsletter Forum. This is for the cannabis stocks forum & discussion. Feel free to find your favorite cannabis stocks and contribute content as you please; content that continues the discussion of, and analysis of, cannabis stocks. – D. H. Taylor

Clear all

CURE Pharmaceutical Receives Patent Approval for Its CUREfilm Blue(TM) Technology

2 Posts
1 Users
Reputable Member
Joined: 1 year ago
Posts: 156
Topic starter  

 I posted the article below as well as another product of CURR that uses the Curefilm technology for other applications.


Oral Thin Film Wellness

Consumer Branded CUREfilm®

Nutri-Strips are the more effective alternative to traditional supplements. Available worldwide, this scientific breakthrough is the result of decades-long experience and 16 issued patents.


Products include:

Sleep A.S.A.P


480w" data-src="" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" />

CURE Pharmaceutical Receives Patent Approval for Its CUREfilm Blue(TM) Technology

7:30 am ET November 16, 2021 (BusinessWire) Print

CURE Pharmaceutical Holding Corp. (OTC: CURR), a technology focused, vertically integrated drug delivery and product development company focused on pharmaceutical and health & wellness products, announced today that it received an issue notification from the U.S. Patent Office (USPTO) stating that U.S. Patent No. 11,179,331 (the '331 patent) is set to issue on November 23, 2021. The '331 patent, entitled "Oral Soluble Film Containing Sildenafil Citrate," covers the product CUREfilm Blue(TM), an oral soluble film of sildenafil citrate (the active ingredient present in Viagra(R)1) for the treatment of erectile dysfunction (ED). CURE is seeking approval of this product via the 505(b)(2) regulatory pathway.

CUREfilm Blue(TM) utilizes the Company's patented and proprietary fast-dissolving drug delivery platform, known as CUREfilm(TM), to deliver the active pharmaceutical ingredient (API) sildenafil citrate. By innovating beyond the traditional pharmaceutical delivery of pills and solutions, CURE is advancing this uniquely discrete, convenient and portable oral film product for achieving a better patient experience. The '331 patent highlights several key aspects of the CUREfilm Blue(TM), such as a balance of performance characteristics (e.g., fast-dissolving and early onset of action) and physical parameters (e.g., large mass and small thickness), while it can be administered with or without water or beverage.

The global erectile dysfunction drug market is projected to grow at a CAGR of 6% and reach approximately USD$6.6 billion by 2025 with sildenafil representing a majority of the market, according to a report by QYR Research.

About CURE Pharmaceutical Holding Corp.

CURE Pharmaceutical(R) is the pioneering developer of CUREform(TM), a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients. As a vertically integrated company, CURE's 25,000 square foot, FDA-registered, NSF(R) and cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.

Forward Looking Statement

Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"), which are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions. The forward-looking statements in this press release reflect CURE's judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements.

(1)Viagra(R) is a registered trademark of Pfizer Inc.

View source version on

SOURCE: CURE Pharmaceutical Holding Corp.

Ina McGuinness 

Reputable Member
Joined: 1 year ago
Posts: 156
Topic starter  

I think this technology and several similar ones will at some point become a world wide method to apply medications, including cannabis.

I hope people do their DD on this sort of thing. I am Not saying to buy this stock at all.

I think various oral strip technologies will be used, and are used now, but in clinical trials for cannabis, and various medicines for PTSD, anxiety, addictions, Alzheimers, depression, ect, etc.

Tilray is  in arbitration right now, I think with another company I own shares of. IGXT. they have a deal with IGXT, and, well, its getting a bit ugly.

I think IGXT has a similar technology to one of CURR's.

I think there are many companies developing similar  technologies to get medicines into people, and I think there is plenty of room for all of them at this point.


I think there might end up being some consolidation of these type of companies. I think large cannabis companies like Tilray will sign deals like tilray did with Integenx, or do licensing deals, or flat out buy some of these companies, and tyr and keep the technologies for themselves, so they can control producttion and distribution. Just my thoughts and opinions here.



Leave a reply

Author Name

Author Email

Title *

Maximum allowed file size is 10MB

Preview 0 Revisions Saved

Copyright Cannabis Investing Newsletter 2021 - 2022